

31 July 2021

USD I CLASS

Fund Information

Fund Name	GuardCap Global Equity Fund
Fund Manager	GuardCap Asset Management Limited
Fund Inception	10 December 2014
Share Class Inception	10 December 2014
Share Class	USD I Class
Style	Growth / Quality Large-Mid Cap. Bottom-Up Fundamental
Legal Status	UCITS
Bloomberg	GCGLEIU
ISIN	IE00BSJCNS13
WKN	A2AELB
Number of Holdings	20-25
Liquidity	Daily at NAV
Annual Management Fee	0.80%
Minimum Investment	\$500,000
Benchmark	MSCI World Index (Net) US\$
Number of Stocks	25
Net Exposure	98.4%
Fund Size	\$3.22 billion
Strategy Size	\$12.68 billion*
Active Share	92.2%

*Based on estimates and is not official

Investment Objective

The investment objective of the Fund is to seek long-term growth of capital with lower than market volatility by investing primarily in equity and similar securities issued by high quality companies listed on Recognised Markets in countries which are members of the Organisation for Economic Co-operation and Development ("OECD").

Investment Process

- Investment philosophy: Growth drives returns; quality protects against downside; valuation matters
- Focused "total immersion" bottom-up analysis of selected "high confidence pool" of stocks
- Concentrated global equity long-only strategy with 20-25 high quality growth companies
- Benchmark agnostic, unconstrained portfolio construction; high active share

Performance Analysis

	Fund %	Benchmark %	Relative Return %
1 Month	2.69	1.79	0.90
3 Months	6.32	4.80	1.52
YTD	13.41	15.07	-1.66
1 Year	29.95	35.07	-5.12
Annualised 3 Year	16.11	14.49	1.62
Annualised 5 Year	17.79	14.29	3.50
Annualised Since Inception*	16.00	11.36	4.64

*Inception date 10/12/14. Past performance results are no indication of future results.

Calendar Year Performance

	Fund %	Benchmark %	Relative Return %
2015	8.96	-0.87	9.83
2016	6.38	7.51	-1.13
2017	32.21	22.40	9.81
2018	1.19	-8.71	9.90
2019	28.68	27.67	1.01
2020	17.95	15.90	2.05

*Past performance results are no indication of future results.

Risk Analysis

Since Inception	Fund	Benchmark
Tracking Error	4.96	
Standard Deviation	12.73	14.38
Information Ratio	0.96	---
Sharpe Ratio*	1.19	0.73
Upside Market Capture	101.07	100.00
Downside Market Capture	75.49	100.00
Batting Average	0.66	

*Sharpe ratio calculated using Bloomberg US Generic Govt. 3 Month Yield

Fund Ratings*

Morningstar Analyst Rating™

Silver

Overall Morningstar Rating™



Morningstar Sustainability Rating™



Morningstar Low Carbon Designation™




Sauren Fondsmanager Rating™




Quantalys Rating™



Geographic Allocation (%)



Sector Allocation (%)



Top 5 Holdings

	Portfolio Weight
Alphabet	7.74%
CME Group	6.80%
EssilorLuxottica	6.60%
Mastercard	5.98%
Booking Holdings	5.46%

Investment Team

Michael Boyd
 Giles Warren
 Bojana Bidovec
 Orlaith O'Connor

Monthly Contributors / Detractors

	Contribution to Portfolio Return
+ Alphabet	0.79%
+ Novo Nordisk	0.49%
+ Nike	0.39%
- Reckitt Benckiser	-0.42%
- Yum China	-0.28%
- Fanuc	-0.25%

YTD Contributors / Detractors

	Contribution to Portfolio Return
+ Alphabet	3.65%
+ Illumina	1.55%
+ Novo Nordisk	1.45%
- MarketAxess	-0.43%
- Reckitt Benckiser	-0.39%
- Fanuc	-0.30%

Manager Commentary

The top contributors to performance year to date were **Alphabet, Illumina and Novo Nordisk**.

Alphabet reported another quarter of exceptional growth. In Q2, organic revenue grew 57% and operating margin almost doubled to 31%. This growth reflected the lapping of the impact of COVID-19, elevated consumer activity online, broad-based increases in advertiser spending and "excellent ongoing execution". **Illumina** is the leader in gene sequencing technology, ahead of competition in terms of cost and accuracy. Its clinical markets, including oncology, reproductive health and genetic disease testing, are expanding as reimbursement increases, patient awareness grows and more sequencing applications enter the clinic. Ramping population sequencing programs are contributing to the robust growth in the research business. Q2 revenue grew 78%. **Novo Nordisk** is the leader in the global diabetes and obesity markets with shares of 29% and 67% respectively. Wegovy, its once weekly injection obesity drug, that can reduce body weight by as much as 18%, had a very promising launch in June. It also initiated a Phase 3 programme for its compound semaglutide as a possible treatment for Alzheimer's.

The top detractors year to date were **MarketAxess, Reckitt Benckiser and Fanuc**.

MarketAxess is the leading electronic bond trading platform and a beneficiary of the secular trend of increasing penetration of electronic trading in global credit markets. Lower interest rate volatility in 2021 has temporarily put pressure on its volumes, revenues and market share and the stock has drifted off following a very strong performance in 2020. **Reckitt Benckiser** is the world's leading consumer health and hygiene company and benefits from secular trends such as the pressure on state-funded health and resulting increase in self-care, increased life expectancy, focus on well-being, and growing global population. Q2 results suffered from tough comparisons with the same period in 2020 when the business benefited from strong, pandemic-related demand for its hygiene products. **Fanuc** is a Japanese company that manufactures robots and pioneered the automation of machine tools and the development of computer numeric controls for factory automation. It is well-placed to benefit from increasing automation across industries, a trend accelerated by COVID-19. The stock, in tandem with the Nikkei index, has lagged a strong global equity market.

Disclaimer:

Issued by GuardCap Asset Management Limited which is authorised and regulated by the Financial Conduct Authority. This document includes information concerning financial markets that was developed at a particular point in time and is subject to change at any time, without notice, and without update. This document may also include forward looking statements concerning anticipated results, circumstances, and expectations regarding future events. Forward-looking statements require assumptions to be made and are, therefore, subject to inherent risks and uncertainties. There is significant risk that predictions and other forward looking statements will not prove to be accurate. Investing involves risk. Equity markets are volatile and will increase and decrease in response to economic, political, regulatory and other developments. Investment funds are not guaranteed, their values change frequently and past performance is not a reliable indicator of future results. This information is for general information purposes only and is not intended as legal, tax, accounting, securities, or investment advice. This information is not intended for distribution into any jurisdiction where such distribution is restricted by law or regulation. It shall under no circumstances be considered an offer or solicitation to deal in any product mentioned herein. GuardCap Asset Management Limited is the Manager of the Fund and an indirect, wholly-owned subsidiary of Guardian Capital Group Limited, a publicly traded firm listed on the Toronto Stock Exchange. For further information on GuardCap Asset Management Limited, or this Fund please visit www.guardcap.co.uk to view the Prospectus, KIID and other relevant documents. **Note to Swiss Investors Only: This is marketing information. Investment in investment funds is subject to market risks. Past performance results are no indication of future results. Especially performance results referring to a period of less than twelve months are no reliable indicator for future results due to the short comparison period. Issuance and redemption commissions are not included in the performance figures. The domicile of the Fund is Ireland. For interested parties, the prospectus, the Key Investor Information Documents (KIIDs), the memorandum of articles as well as the annual and semi-annual reports may be obtained free of charge from the Swiss representative and paying agent in Switzerland: RBC Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Bleicherweg 7, CH-8027 Zurich.**

*Morningstar Analyst Rating™ is Morningstar's forward looking fund rating. Overall Morningstar Rating™ is an assessment of a fund's past performance, based on both return and risk and shows how similar investments compare with their competitors. The Morningstar Sustainability Rating™ is a measure of how well the portfolio holdings are managing their ESG Risk relative to the portfolio's Global Category peer group. Sustainalytics provides company-level analysis used in the calculation of Morningstar's Historical Sustainability Score. The Morningstar Low Carbon Designation™ is Sustainalytics' evaluation of the degree to which a firm's activities and products are aligned with the transition to a low-carbon economy. Investment decisions should not be based on a high rating alone. All data is as at the document date unless indicated otherwise. © 2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For more detailed information about Morningstar's Analyst Rating, including its methodology, please go to: <https://shareholders.morningstar.com/investor-relations/governance/Compliance--Disclosure/default.aspx> and <http://corporate1.morningstar.com/SustainableInvesting/>.

Quantalys Rating™ is Quantalys' fund rating. For more information about Quantalys ratings and Quantalys' ratings methodology, please see <https://www.quantalys.com/espace/listeProduit/3480> and <https://quantalys.com/Whoarewe/Methodology>.



For More Information

Michael Hughes
mhughes@guardiancapital.com | +44-20-7907-2405

Alexandra Schwarz
aschwarz@guardiancapital.com | +44-20-7907-2011